Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Orally administered AT-56 (<30 mg/kg body weight) decreases the PGD2 production to 40% in the brain of H-PGDS-deficient mice after a stab wound injury in a dose-dependent manner without affecting the production of PGE2 and PGF2α and also suppresses the accumulation of eosinophils and monocytes in the bronco-alveolar lavage fluid from the antigen-induced lung inflammation model of human L-PGDS-transgenic mice
COC(=O)NCCO[C@H]([C@H]1CN(CCC1)C(=O)NC[C@H](C[C@H]1CCCOC1)NC)C1=CC(Cl)=CC=C1
and in humans infected with hepatitis C virus
InChiKey: COCMHKNAGZHBDZ-UHFFFAOYSA-N
InChi: InChI=1S/C21H21NO3S2/c1-17-8-14-21(15-9-17)27(23
Carotegrast methyl Catalog No.:M26697-C Orally administered AT-56 (<30 mg/kgCarotegrast methyl (AJM300) is an orally active and selective 4 integrin antagonist. HCA2969, an active metabolite of Carotegrast methyl, is a specific and dual 41 47 integrin antagonist. Carotegrast methyl prevents the development of colitis in mice. Product information CAS Number: 401905 67 7 Molecular Weight: 569. 44 Formula: C28H26Cl2N4O5 Chemical Name: methyl (2S) 2 [(2,6 dichlorophenyl)formamido] 3 {4 [6 (dimethylamino) 1 methyl 2,4 dioxo
US$ 1190.00
US$ 1237.50
US$ 3975.00
US$ 3262.50
US$ 68.00
US$ 75.00
US$ 75.00
US$ 38.00
US$ 52.00
US$ 178.00
US$ 2475.00
US$ 1375.00
US$ 125.00
US$ 337.50
US$ 937.50